Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Metformin – Forschungsarchiv – Seite 23 von 24 | SupStack

Metformin – Forschungsarchiv

Studien 2051–2100 von 2110, neueste zuerst

Die 1000 neuesten Studien – mit Evidenz-Zusammenfassung, Filtern und Suche – stehen auf der Hauptseite. Dieses Archiv listet die übrigen, 50 pro Seite. Zurück zur Hauptseite

2051RCT1996

Sambol NC, Chiang J, O'Conner M, Liu CY, Lin ET, Goodman AM · J Clin Pharmacol (1996)

Für dieses Zitat ist keine Zusammenfassung hinterlegt — öffne die Arbeit, um das Abstract zu lesen.

Metformin – Forschungsarchiv

Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus.

A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.

Different effect of acute and chronic oral metformin administration on glucose and insulin response to bread and to pasta in non-insulin dependent diabetic patients.

Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.

Therapeutic effect of glibenclamide in a fixed combination with metformin or phenformin in NIDDM patients.

The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.

Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance.

Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man.

Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease.

Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus.

Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas.

Influence of food on the disposition of the antidiabetic drug metformin in diabetic patients at steady-state.

United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.

Short administration of metformin improves insulin sensitivity in android obese subjects with impaired glucose tolerance.

Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women.

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis.

Effects of metformin and metoprolol CR on hormones and fibrinolytic variables during a hyperinsulinemic, euglycemic clamp in man.

Reduction of the acute bioavailability of metformin by the alpha-glucosidase inhibitor acarbose in normal man.

Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes.

The effect of metformin and insulin on sympathetic nerve activity, norepinephrine spillover and blood pressure in obese, insulin resistant, normoglycemic, hypertensive men.

One year comparative trial of metformin and glipizide in type 2 diabetes mellitus.

Effects of metformin treatment on whole-body and splanchnic amino acid turnover in mild type 2 diabetes.

Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination.

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

Metformin and metoprolol CR treatment in non-obese men.

Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women.

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

Short-term effects of metformin on insulin sensitivity and sodium homeostasis in essential hypertensives.

Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients.

The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes.

Comparison of combined therapies in treatment of secondary failure to glyburide.

Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM.

Treatment of NIDDM patients with secondary failure to glyburide: comparison of the addition of either metformin or bed-time NPH insulin to glyburide.

BIGPRO (biguanides and the prevention of the risk of obesity): study design. A randomized trial of metformin versus placebo in the correction of the metabolic abnormalities associated with insulin resistance.

The insulin sparing effect of metformin in insulin-treated diabetic patients.

Double-blind evaluation of efficacy and tolerability of metformin in NIDDM.

Effects of metformin and glibenclamide alone and in combination on serum lipids and lipoproteins in patients with non-insulin-dependent diabetes mellitus.

Comparative efficacy of metformin and glibenclamide in patients with non-insulin-dependent diabetes mellitus.

Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles.

[Glycemic equilibrium and weight evolution in diabetics taking metformin].

Treatment strategies for secondary sulfonylurea failure. Should we start insulin or add metformin? Is there a place for intermittent insulin therapy?

Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD.

Sulfonylurea-metformin-combination versus sulfonylurea-insulin-combination in secondary failures of sulfonylurea monotherapy. Results of a prospective randomized study in 50 patients.

Effects of metformin on dyslipoproteinemia in non-insulin-dependent diabetes mellitus.

Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes.

Comparison of tolbutamide and metformin in elderly diabetic patients.

Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients.

Cholesterol lowering effect of metformin in combined hyperlipidemia: placebo controlled double blind trial.